PPARα agonist 5
PPARα agonist 5 is an orally available, selective partial agonist of PPARα (EC50: 3 nM). PPARα agonist 5 reduces lipid accumulation and upregulates key PPARα target genes, exerting anti-fatty liver effects. PPARα agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC50: 79.1 μM). PPARα agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia.
For research use only. We do not sell to patients.
- Formula: C25H20O3
- Molecular Weight:368.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
PPARα 3 nM (EC50) |
PPAR-γ 1.66 μM (EC50) |
PPARδ >25 μM (EC50) |
In Vitro
PPARα agonist 5 (Compound (S)-2) selectively agonizes PPARα in HepG2 cells (EC50: 3 nM), is approximately 550-fold more active against PPARα than against PPARγ (EC50: 1.66 μM), and has no significant activity against PPARδ[1].
PPARα agonist 5 (0.025-25 μM, 24 h/15days) significantly reduces lipid accumulation induced by oleic acid in HepaRG cells and upregulated PPARα target genes associated with fatty acid oxidation, indicating that it exerts anti-fatty liver effects by activating lipid metabolism pathways[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:oleic acid (500 μM) treated HepaRG cells
-
Concentration:0.025, 0.25, 2.5, 25 μM
-
Incubation Time:oleic acid for 24 hours, then for another 24 hours or 15 days
-
Result:Significantly upregulated fatty acid oxidation-related genes (CPT1a, HMGCS2, PDK4), and the activation of these genes indicated that it promoted fatty acid oxidation and reduced liver fat accumulation.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss Albino mice (male, weight 25-30 g) injected with Tyloxapol (400 mg/kg)[1]
-
Dosage:(1, 3, 7.5 mg/kg)
-
Administration:p.o. 7 consecutive days
-
Result:Significantly reduced total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-C) and very low-density lipoprotein (VLDL-C) levels.
Showed significant hypoglycemic effects, which were associated with its partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B).
Was non-toxic to arteries, kidneys, liver and pancreas at a dose of 3 mg/kg, and was able to reverse organ damage caused by hyperlipidemia.
Chemical Information
-
Molecular Weight 368.42
-
Formula C25H20O3
-
SMILES
O=C(O)[C@@](C1=CC=CC=C1)(C)OC(C=C2)=CC=C2C3=C(C=CC=C4)C4=CC=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
3T3-L1 preadipocyte-to-adipocyte differentiation
3T3-L1 preadipocytes are induced to differentiate after growth arrest using adipogenic media containing insulin, dexamethasone, and IBMX; differentiation is assessed by lipid-droplet accumulation, triglyceride increase, Oil Red O staining, and adipocyte-marker induction such as PPARγ and C/EBPα.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Lipid Droplets: Oil Red O/Sudan Dye Lipid Staining
Lipid droplets are intracellular organelles with a neutral-lipid core that stores triacylglycerols and sterol esters, and Oil Red O or Sudan dyes detect these hydrophobic lipid deposits by partitioning into retained lipids in fresh or frozen specimens. Oil Red O stains neutral triglycerides and lipids in frozen tissue sections or air-dried cytologic preparations, while Sudan Black B has also been used as a histochemical fat stain for lipid-rich tissue structures.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)